A census of human cancer genes

A central aim of cancer research has been to identify the mutated genes that are causally implicated in oncogenesis ('cancer genes'). After two decades of searching, how many have been identified and how do they compare to the complete gene set that has been revealed by the human genome sequence? We have conducted a 'census' of cancer genes that indicates that mutations in more than 1% of genes contribute to human cancer. The census illustrates striking features in the types of sequence alteration, cancer classes in which oncogenic mutations have been identified and protein domains that are encoded by cancer genes.

[1]  R. Weinberg,et al.  Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Cooper,et al.  Transforming activity of human tumor DNAs. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Eugenio Santos,et al.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene , 1982, Nature.

[4]  Cori Bargmann,et al.  Mechanism of activation of a human oncogene , 1982, Nature.

[5]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[6]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[8]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[9]  Bert Vogelstein,et al.  Hypermutability and mismatch repair deficiency in RER+ tumor cells , 1993, Cell.

[10]  C. Carcano,et al.  Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A , 1993, Molecular and cellular biology.

[11]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[12]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[13]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[14]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[15]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[16]  S Gill,et al.  The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. , 1996, Human molecular genetics.

[17]  Sheila Seal,et al.  BRCA2 mutations in primary breast and ovarian cancers , 1996, Nature Genetics.

[18]  L. Mulligan,et al.  Mutations of the RET proto‐oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease , 1997, Human mutation.

[19]  H. Ostrer,et al.  Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC , 1997, Nature Genetics.

[20]  M. Loda,et al.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.

[21]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[22]  W. Marston Linehan,et al.  Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.

[23]  R. Richards,et al.  Fragile sites still breaking. , 1998, Trends in genetics : TIG.

[24]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[25]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[26]  K. Kinzler,et al.  Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. , 1999, Cancer research.

[27]  B. Spiegelman,et al.  PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma , 2000 .

[28]  A. Bednarek,et al.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. , 2000, Cancer research.

[29]  C. Stratakis,et al.  Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex , 2000, Nature Genetics.

[30]  Victor E. Velculescu,et al.  Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis , 2001, Nature Genetics.

[31]  M. Cleary,et al.  Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins , 2001, Oncogene.

[32]  G. Thomas,et al.  Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers. , 2001, Human molecular genetics.

[33]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[34]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[35]  S. Baylin,et al.  Altered methylation patterns in cancer cell genomes: cause or consequence? , 2002, Cancer cell.

[36]  Y. Nikiforov.  RET/PTC rearrangement in thyroid tumors , 2002, Endocrine pathology.

[37]  A. Duval,et al.  Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. , 2002, Cancer research.

[38]  David Sidransky,et al.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.

[39]  P. Sorensen,et al.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.

[40]  Shih-Jen Hwang,et al.  Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. , 2003, American journal of human genetics.

[41]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.